OPHT up +1.80% percent right now. $OPHT High is at 43.72 and the Low 41.17 with current volume of 100,020.
Recent News posted below.
OPHT Ophthotech Corp Recent Headline News
Ophthotech's (OPHT) CEO Dr. David Guyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 11:12AM CST
OPHT: 41.56 (+0.43)
Ophthotech beats 3Q profit forecasts
Automated Insights - Tue Nov 11, 6:34AM CST
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Tuesday reported net income of $10.9 million in its third quarter.
OPHT: 41.56 (+0.43)
Ophthotech EPS of $0.31
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 5:44AM CST
OPHT: 41.56 (+0.43)
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.98 (+0.06), OPHT: 41.56 (+0.43)
Ophthotech Provides Business Update and Reports Third Quarter 2014 Financial Results
Business Wire - Tue Nov 11, 5:30AM CST
--- Ophthotech Achieves Enrollment Milestone Triggering Third and Final Tranche in Royalty Financing with Novo A/S -
OPHT: 41.56 (+0.43)
Ophthotech Corporation to Present at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2014 Credit Suisse Annual Healthcare Conference in Phoenix, Arizona on Wednesday, November 12, 2014 at 8:00am MST.
OPHT: 41.56 (+0.43)
Ophthotech Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Mon Nov 03, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the third quarter ended September 30, 2014, on Tuesday, November 11, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech's financial results for the third quarter and provide a general business update.
OPHT: 41.56 (+0.43)
3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000 small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 108.81 (-0.01), INSY: 40.34 (+3.28), PTLA: 27.10 (-0.55), PFE: 30.25 (+0.05), MRK: 59.26 (+0.45), OPHT: 41.56 (+0.43), IWM: 117.14 (-0.15), BMY: 58.69 (-0.12), REGN: 398.86 (+12.89)
Ophthotech Corporation Names Todd N. Smith as Chief Commercial Officer
Business Wire - Fri Oct 03, 6:30AM CDT
--- Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -
OPHT: 41.56 (+0.43)
Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
ACE: 110.96 (-0.55), MRK: 59.26 (+0.45), OPHT: 41.56 (+0.43), TBPH: 18.00 (-0.32)
Ophthotech Announces Fovista(R) Phase 2b Independent Analysis Shows that Fovista(R) Anti-PDGF Therapy, Combined with Anti-VEGF Therapy, is Associated with a Reduction of Sub-retinal Fibrosis in Wet AMD Patients
Business Wire - Tue Sep 16, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the Company's Phase 2b trial comparing Fovista(R) (1.5mg) combination therapy with Lucentis(R) (0.5mg) versus Lucentis(R) (0.5mg) monotherapy will be presented at the American Academy of Ophthalmology 2014 Annual Meeting in Chicago, Illinois. Sub-retinal fibrosis is a major cause of visual loss in wet age-related macular degeneration (AMD) patients treated with the current standard of care, anti-VEGF monotherapy, according to third party studies(1).
OPHT: 41.56 (+0.43)
Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista(R)
Business Wire - Mon Sep 08, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This enrollment milestone payment from Novartis was triggered as a result of Ophthotech reaching the first enrollment goal under the agreement in its pivotal, multi-national Fovista(R) Phase 3 clinical program and is the first of a total of $130 million in potential enrollment-based milestones under the agreement. Fovista(R), Ophthotech's anti-platelet-derived growth factor (PDGF) compound, is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of wet AMD.
OPHT: 41.56 (+0.43), NVS: 92.57 (-0.06)
Ophthotech Corporation to Present at the 2014 Morgan Stanley Global Healthcare Conference
Business Wire - Tue Sep 02, 6:30AM CDT
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 9, 2014 at 1:30 p.m. Eastern Time.
OPHT: 41.56 (+0.43), MS: 35.76 (-0.12)
Ophthotech Reports Second Quarter 2014 Financial Results and Provides Business Update
Business Wire - Wed Aug 06, 5:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today provided an update on the Company's business and announced financial results for the second quarter ended June 30, 2014.
OPHT: 41.56 (+0.43)
Ophthotech Initiates First of Several Expansion Studies to Further Evaluate Fovista(R) (Anti-PDGF) Therapy in Patients with Wet Age-Related Macular Degeneration
Business Wire - Tue Aug 05, 6:30AM CDT
--- Fovista(R) Combination Therapy Phase 2b Subgroup Analysis for Reduction of Sub-retinal Fibrosis to be Presented at the 2014 Annual Meeting of the American Academy of Ophthalmology -
OPHT: 41.56 (+0.43)
Ophthotech Corporation to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
Business Wire - Tue Jul 29, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the second quarter ended June 30, 2014, on Wednesday, August 6, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech's financial results for the second quarter and provide a general business update.
OPHT: 41.56 (+0.43)
Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About
Motley Fool Staff - Motley Fool - Sat Jul 19, 8:11AM CDT
In the Fed's Monetary Policy Report submitted July 15th, Fed chair Janet Yellen called out social media and biotech stocks as having valuations that appear "substantially stretched" (i.e. overvalued). We asked our top contributors for stocks which...
NVAX: 5.34 (+0.13), SRPT: 15.52 (-0.52), OPHT: 41.56 (+0.43)
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
EBS: 24.50 (+0.55), NURO: 1.64 (-0.02), OPHT: 41.56 (+0.43), ANAC: 31.19 (+0.65), WLP: 126.81 (+1.31)
Is Opthotech Your Next Multibagger Stock?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:00PM CDT
Opthotech has had quite a run in the past two years. Shares have nearly doubled as investors have grown increasingly confident that Fovista, its treatment for wet age-related macular degeneration, can eventually reach the market. If it does,...
OPHT: 41.56 (+0.43), REGN: 398.86 (+12.89), NVS: 92.57 (-0.06)
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 08, 12:41PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
BDSI: 16.48 (+0.28), KNDI: 15.45 (+0.59), BB.TO: 12.52 (-0.11), ATRM: 3.77 (-0.04), MARK: 4.30 (-0.01), BBRY: 11.04 (-0.05), OPHT: 41.56 (+0.43), BRID: 7.90 (unch), CLDN: 12.23 (+0.63), DJCO: 202.00 (+2.00), CBPO: 66.26 (+1.96), CLBH: 9.48 (-0.44), HMNF: 12.50 (unch), PENX: 18.80 (unch), CNIT: 4.09 (+0.18), FCLF: 9.03 (+0.03)
Recent News posted below.
OPHT Ophthotech Corp Recent Headline News
Ophthotech's (OPHT) CEO Dr. David Guyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 11:12AM CST
OPHT: 41.56 (+0.43)
Ophthotech beats 3Q profit forecasts
Automated Insights - Tue Nov 11, 6:34AM CST
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Tuesday reported net income of $10.9 million in its third quarter.
OPHT: 41.56 (+0.43)
Ophthotech EPS of $0.31
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 5:44AM CST
OPHT: 41.56 (+0.43)
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.98 (+0.06), OPHT: 41.56 (+0.43)
Ophthotech Provides Business Update and Reports Third Quarter 2014 Financial Results
Business Wire - Tue Nov 11, 5:30AM CST
--- Ophthotech Achieves Enrollment Milestone Triggering Third and Final Tranche in Royalty Financing with Novo A/S -
OPHT: 41.56 (+0.43)
Ophthotech Corporation to Present at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2014 Credit Suisse Annual Healthcare Conference in Phoenix, Arizona on Wednesday, November 12, 2014 at 8:00am MST.
OPHT: 41.56 (+0.43)
Ophthotech Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Mon Nov 03, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the third quarter ended September 30, 2014, on Tuesday, November 11, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech's financial results for the third quarter and provide a general business update.
OPHT: 41.56 (+0.43)
3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000 small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 108.81 (-0.01), INSY: 40.34 (+3.28), PTLA: 27.10 (-0.55), PFE: 30.25 (+0.05), MRK: 59.26 (+0.45), OPHT: 41.56 (+0.43), IWM: 117.14 (-0.15), BMY: 58.69 (-0.12), REGN: 398.86 (+12.89)
Ophthotech Corporation Names Todd N. Smith as Chief Commercial Officer
Business Wire - Fri Oct 03, 6:30AM CDT
--- Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -
OPHT: 41.56 (+0.43)
Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
ACE: 110.96 (-0.55), MRK: 59.26 (+0.45), OPHT: 41.56 (+0.43), TBPH: 18.00 (-0.32)
Ophthotech Announces Fovista(R) Phase 2b Independent Analysis Shows that Fovista(R) Anti-PDGF Therapy, Combined with Anti-VEGF Therapy, is Associated with a Reduction of Sub-retinal Fibrosis in Wet AMD Patients
Business Wire - Tue Sep 16, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the Company's Phase 2b trial comparing Fovista(R) (1.5mg) combination therapy with Lucentis(R) (0.5mg) versus Lucentis(R) (0.5mg) monotherapy will be presented at the American Academy of Ophthalmology 2014 Annual Meeting in Chicago, Illinois. Sub-retinal fibrosis is a major cause of visual loss in wet age-related macular degeneration (AMD) patients treated with the current standard of care, anti-VEGF monotherapy, according to third party studies(1).
OPHT: 41.56 (+0.43)
Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista(R)
Business Wire - Mon Sep 08, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This enrollment milestone payment from Novartis was triggered as a result of Ophthotech reaching the first enrollment goal under the agreement in its pivotal, multi-national Fovista(R) Phase 3 clinical program and is the first of a total of $130 million in potential enrollment-based milestones under the agreement. Fovista(R), Ophthotech's anti-platelet-derived growth factor (PDGF) compound, is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of wet AMD.
OPHT: 41.56 (+0.43), NVS: 92.57 (-0.06)
Ophthotech Corporation to Present at the 2014 Morgan Stanley Global Healthcare Conference
Business Wire - Tue Sep 02, 6:30AM CDT
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 9, 2014 at 1:30 p.m. Eastern Time.
OPHT: 41.56 (+0.43), MS: 35.76 (-0.12)
Ophthotech Reports Second Quarter 2014 Financial Results and Provides Business Update
Business Wire - Wed Aug 06, 5:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today provided an update on the Company's business and announced financial results for the second quarter ended June 30, 2014.
OPHT: 41.56 (+0.43)
Ophthotech Initiates First of Several Expansion Studies to Further Evaluate Fovista(R) (Anti-PDGF) Therapy in Patients with Wet Age-Related Macular Degeneration
Business Wire - Tue Aug 05, 6:30AM CDT
--- Fovista(R) Combination Therapy Phase 2b Subgroup Analysis for Reduction of Sub-retinal Fibrosis to be Presented at the 2014 Annual Meeting of the American Academy of Ophthalmology -
OPHT: 41.56 (+0.43)
Ophthotech Corporation to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
Business Wire - Tue Jul 29, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the second quarter ended June 30, 2014, on Wednesday, August 6, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech's financial results for the second quarter and provide a general business update.
OPHT: 41.56 (+0.43)
Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About
Motley Fool Staff - Motley Fool - Sat Jul 19, 8:11AM CDT
In the Fed's Monetary Policy Report submitted July 15th, Fed chair Janet Yellen called out social media and biotech stocks as having valuations that appear "substantially stretched" (i.e. overvalued). We asked our top contributors for stocks which...
NVAX: 5.34 (+0.13), SRPT: 15.52 (-0.52), OPHT: 41.56 (+0.43)
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
EBS: 24.50 (+0.55), NURO: 1.64 (-0.02), OPHT: 41.56 (+0.43), ANAC: 31.19 (+0.65), WLP: 126.81 (+1.31)
Is Opthotech Your Next Multibagger Stock?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:00PM CDT
Opthotech has had quite a run in the past two years. Shares have nearly doubled as investors have grown increasingly confident that Fovista, its treatment for wet age-related macular degeneration, can eventually reach the market. If it does,...
OPHT: 41.56 (+0.43), REGN: 398.86 (+12.89), NVS: 92.57 (-0.06)
Nasdaq stocks posting largest percentage increases
AP - Tue Jul 08, 12:41PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
BDSI: 16.48 (+0.28), KNDI: 15.45 (+0.59), BB.TO: 12.52 (-0.11), ATRM: 3.77 (-0.04), MARK: 4.30 (-0.01), BBRY: 11.04 (-0.05), OPHT: 41.56 (+0.43), BRID: 7.90 (unch), CLDN: 12.23 (+0.63), DJCO: 202.00 (+2.00), CBPO: 66.26 (+1.96), CLBH: 9.48 (-0.44), HMNF: 12.50 (unch), PENX: 18.80 (unch), CNIT: 4.09 (+0.18), FCLF: 9.03 (+0.03)
